- Home
- LIDR vs BLRX Comparison
LIDR vs BLRX Comparison
Compare LIDR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- BLRX
- Stock Information
- Founded
- LIDR 2013
- BLRX 2003
- Country
- LIDR United States
- BLRX Israel
- Employees
- LIDR N/A
- BLRX N/A
- Industry
- LIDR Auto Parts:O.E.M.
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- BLRX Health Care
- Exchange
- LIDR Nasdaq
- BLRX Nasdaq
- Market Cap
- LIDR 14.8M
- BLRX 15.3M
- IPO Year
- LIDR N/A
- BLRX 2011
- Fundamental
- Price
- LIDR $0.92
- BLRX $4.45
- Analyst Decision
- LIDR Hold
- BLRX Strong Buy
- Analyst Count
- LIDR 1
- BLRX 2
- Target Price
- LIDR N/A
- BLRX $19.00
- AVG Volume (30 Days)
- LIDR 577.6K
- BLRX 2.1M
- Earning Date
- LIDR 08-04-2025
- BLRX 08-14-2025
- Dividend Yield
- LIDR N/A
- BLRX N/A
- EPS Growth
- LIDR N/A
- BLRX N/A
- EPS
- LIDR N/A
- BLRX N/A
- Revenue
- LIDR $246,000.00
- BLRX $22,340,000.00
- Revenue This Year
- LIDR $2,677.23
- BLRX N/A
- Revenue Next Year
- LIDR $409.09
- BLRX N/A
- P/E Ratio
- LIDR N/A
- BLRX N/A
- Revenue Growth
- LIDR N/A
- BLRX 91.68
- 52 Week Low
- LIDR $0.49
- BLRX $2.30
- 52 Week High
- LIDR $4.30
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- LIDR 65.47
- BLRX 50.17
- Support Level
- LIDR $0.71
- BLRX $3.79
- Resistance Level
- LIDR $0.88
- BLRX $4.62
- Average True Range (ATR)
- LIDR 0.09
- BLRX 0.56
- MACD
- LIDR 0.00
- BLRX -0.13
- Stochastic Oscillator
- LIDR 89.21
- BLRX 21.79
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.